Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP)
The PTC-CTP grant from the Alzheimer's Association funds biomarker-driven clinical trials testing combination therapies for Alzheimer’s disease and related dementias.
Funder: Alzheimer's Association
Due Dates: October 20, 2026 (Letter of Intent) | October 22, 2026 (LOI, ISTAART Members) | December 15, 2026 (Application) | December 17, 2026 (Application, ISTAART Members)
Funding Amounts: Up to $1,000,000 (Phase 1); up to $2,000,000 (Phase 2–3, 2–3 years); rare cases up to $3,000,000 considered.
Summary: Funds innovative clinical trials combining multiple therapeutic strategies for Alzheimer’s disease, emphasizing biomarker-driven approaches.
Key Information: Only one application per PI per cycle; LOI required before full application; for-profit and international applicants eligible.
Description
This program supports translational research advancing innovative, biomarker-informed combination clinical trials for Alzheimer’s disease and related dementias. Projects must combine at least two therapeutic strategies—such as drug-drug, drug-behavioral, or drug-device interventions—and rigorously justify the scientific rationale for the combination. The initiative prioritizes trials that use biomarker-based inclusion criteria and outcomes, and that thoughtfully address the integration or exclusion of anti-amyloid monoclonal antibodies. The goal is to accelerate the development and clinical testing of effective combination therapies.
